血液･固形腫瘍診断マニュアル　改訂版

出版社： フジメディカル出版
著者：
発行日： 2002-10-01
分野： 臨床医学：内科  >  内科学一般
ISBN： 4939048195
電子書籍版： 2002-10-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

4,950 円(税込)

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

2,475 円(税込)

購入する

商品紹介

造血器腫瘍の治療においては、一部白血病・リンパ腫などのように、分子標的療法や抗体療法が一般化し、飛躍的に予後が改善した疾患軍も出現している。今後、分子生物学、免疫学的手法を駆使した詳細な診断が、より的確な治療に結びつくのは明白である。今回改訂を行った本書が、このような診療の中で役立つことを心から期待したい。

目次

  • 血液・固形腫瘍診断マニュアル　改訂版

    ―　目　次　―

    1．細胞形態、細胞科学に基づく診断

    2．遺伝子診断法
    1)　ブロッティング法
    2)　遺伝子増幅法
    3)　DNAチップ法

    3．腫瘍の遺伝子検査と倫理

    4．染色体検査法
    1)　分染法
    2)　FISH法、間期核FISH法
    3)ＳＫＹ法

    5．細胞免疫学的診断法
    1)　フローサイトメトリー
    2)　CD45ゲーティングを用いた解析

    6．タンパク分析法

    7．検査用検体の処理と保存
    1)　造血器腫瘍（血液・骨髄９
    2)　固形腫瘍

    8．腫瘍の遺伝子・免疫学的診断と臨床的意義
    1)　造血器腫瘍
    2)　固形腫瘍

    9．遺伝子・免疫学的検査の治療への応用

    文献

    <参考資料>
    <カラー図譜>

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1. 細胞形態、細胞化学に基づく診断

P.6 掲載の参考文献
1) Bennett JM et al:Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33(4):451, 1976
PubMed
2) Shafer JA:Preparation of blood films for examination. in Clinical hematology Principles, procedures, correlations, Lippincott, Philadelphia, 1998
 

2. 遺伝子診断法

P.12 掲載の参考文献
1) Southern EM:Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol 98:503, 1975
PubMed
2) Barbacid M:ras genes. Ann Rev Biochem 56:779, 1987
PubMed
3) Bordow SB et al:Prognostic significance of N-myc oncogene expression in childhood neuroblastoma. J Clin Oncol 16:3286, 1998
 
4) Groffen J et al:Philadelphia chromosomal breakpoints are clustered within a limited area, bcr, on chromosome 22. Cell 36:93, 1984
 
5) Golub TR et al:Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 92:4917, 1995
 
6) Takeuchi S et al:TEL is one of the targets for deletion on 12p in many cases of childhood B-lineage acute lymphoblastic leukemia. Leukemia 11:1220, 1997
PubMed
7) Korsmeyer SJ:Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Ann Rev Immunol 10:785, 1992
 
8) van Dongen JJ et al:Arialysis of immunoglobulin and T-cell receptor genes. Part Basic and technical aspects. Clin Chim Acta 198:1, 1991
 
9) Beishuizen A et al:Detection of immunoglobulin heavy-chain gene rearrangements by Southern blot analysis:recommendations for optimal result. Leukemia 7:2045, 1993
PubMed
10) Knudson AG Jr. :Mutation and cancer:Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820, 1971
PubMed
11) Cavenee WK et al:Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779 , 1983
PubMed
12) Hollstein M et al:p53 mutations in human cancers. Science 253:49, 1991
PubMed
13) Seriu T et al:Homogenous deletion of the p16 gene in childhood acute lymphoblastic leukemia. Acute Leukemia VI (Buchner T et al eds), Springer-Verlag, Berlin Heidelberg, 1997, p90
 
14) Saiki RK et al:Enzymatic amplification of beta-globin genomic sequences and rest riction site analysis for diagnosis of sickle cell anemia. Science 230 (4732):1350, 1985
 
15) Mullis KB et al:Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 1 55:335, 1987
 
16) Hansen-Hagge TE et al:Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor delta chain sequences. Blood 74(5):1762, 1989
PubMed
17) Sparkman DR:Paraffin wax as a vapor banier for the PCR. PCR Methods 2(2):180, 1992
 
18) Don RH et al:'Touchdown' PCR to circumvent spurious priming during gene amplification. Nucleic Acids Res 19(14):4008, 1991
 
19) Cheng S et al:Long PCR. Natllre 69:684, 1994
 
20) Akasaka T et al:Application of long-distance polymerase chain reaction to detection of junctional sequences created by chromosomal translocation in mature B-cell neoplasms. Blood 88(3):985, 1996
PubMed
21) Kawasaki ES et al:Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified vitro. Proc Natl Acad Sci USA 85(15):5698, 1988
PubMed
22) Miyoshi H et al:The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript. EMBO J 12(7):2715, 1993
 
23) Kakizuka A et al:Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell 66(4):663, 1991
PubMed
24) Inoue K et al:WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84(9):3071, 1994
 
25) Rabbitts TH:Chromosomal translocations in human cancer. Nature 372(6502):143, 1994
PubMed
26) Lee MS et al:Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 237(4811):175, 1987
 
27) Cheng S et al:Effective amplification of long targets from cloned inserts and human genomic DNA. Proc Natl Acad Sci USA 91(12):5695, 1994
PubMed
28) Akasaka T et al:Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immuboglobulin heavy-chain fusion gene. J Clin Oncol 18(3):510, 2000
 
29) Borrensen AL et al:Detection of base mutation in genomic DNA using denaturing gradient gel electrophoresis (DGGE) followed by transfer and hybridization with gene-specific probes. Mutat Res 202:77, 1988
 
30) Borrensen AL et al:Constant denaturing gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci 88:8405, 1991
 
31) Nedergaard T et al:A one-step DGGE scanning method for detection of mutations in the K-, N-, and H-ras oncogenes:mutations at codons 12, 13 and 61 are rare in B-cell non-Hodgkin's lymphoma. Int J Cancer 71:364, 1997
 
32) Pongers-Willemse MJ et al:Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets. Leukernia 13:110, 1999
 
33) Briet TM et al:Human T cell leukemias with continuous V(D)J recombinase activity for TCR-δ gene deletion. J Immunol 159:4341, 1997
 
34) Beishuizen A et al:Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias:a new molecular target for detection of minimal residual disease. Leukemia 11:2200, 1997
 
35) Breit TM et al:Extensive junctional diversity of γδ T-cell receptors expressed by T-cell acute lymphoblastic leukemia:implications for the detection of minimal residual disease. Leukemia 5:1076, 1991
 
36) Bottaro M et al:Heteroduplex analysis of T cell receptor γ gene rearrangements for diagnosis and monitoring of cutaneous T cell lymphomas. Blood 83:3271, 1994
 
37) Kneba M et al:Analysis of rearranged T-cell receptor β-chain genes by polymerase chain reaction (PCR) DNA sequencing and automated high resolution PCR fragment analysis. Blood 86:3930, 1995
 
38) Wang AM et al:Quantitation of mRNA by the polymerase chain reaction. Proc Natl Acad Sci USA 86:9717, 1989
PubMed
39) Diaco R:Practical considerations for the design of quantitative PCR assays. PCR Strategies Chapter 7, 1995, p84
 
40) Gause WC et al:Use of PCR quantitate relative differences in gene expression. PCR PRIMER, 1995, p293
 
41) Ferre F:Quantitative or semi-quantitative PCR:Reality versus Myth. PCR methods Applic 2:1, 1992
 
42) Raeymaekers L:A commentary on the practical applications of competitive PCR. PCR Methods Applic 5:91, 1995
 
43) Siebert PD et al:PCR MIMICs:Competitive DNA fragments for use in quantitative PCR. PCR2 Chapter 8, 1995, p135
 
44) 川上文清ほか:増幅産物の定量 (2)定量的PCR. 蛋白質 核酸 酵素 41(5):503, 1996
 
45) 中山広樹:細胞工学別冊 バイオ実験イラストレイテッド(3)+ 本当にふえるPCR 第8章, 秀潤社, 東京, 1998, p141
 
46) Tchirkov A et al:Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukemia during interferon-α therapy. Br J Haematol 101:552, 1998
 
47) Tchirkov A et al:Molecular detection of a late-appearing BCR-ABL gene in a child with T-cell acute lymphoblastic leukemia. Ann Hematol 77:55, 1998
 
48) Kuhr T et al:Detection and quantitation of genetically marked acute myeloid leukemia by competitive polymerase chain reaction after autologous bone marrow transplantation. Experimental Hematology 27:266, 1999
PubMed
49) Hosler GA et al:Development and validation of a quantitative polymerase chain reaction assay to evaluate minimal residual disease for T-cell acute lymphoblastic leukemia and follicular lymphoma. Am J pathol 154:lo23, 1999
 
50) Freeman WM et al:Quantitative RT-PCR:Pitfalls and Potential. BioTechniques 26:112, 1999
PubMed
51) Taniguchi T et al:Cyclin D1 overexpression detected by a simple competitive reverse transcription-polymerase chain reaction assay for Lymphoid Malignancies. Jpn J Cancer Res 89:159, 1998
PubMed
52) 島田 敦ほか:急性リンパ性白血病患者におけるcompetitive RT-PCR法を用いたWT1遺伝子mRNAの定量, 日本臨床血液学会, 第38回総会, 演題番号261, 1996
 
53) 島田 敦ほか:急性白血病患者における競合RT-PCR法を用いたflt3 mRNAの定量, 日本臨床血液学会, 第39回総会, 演題番号83, 1997
 
54) 島田 敦ほか:BCR/ABLキメラmRNAの次世代遺伝子検出システムによる定量, 日本血液学会, 第60回総会, 演題番号222, 1998
 
55) Hochhaus A et al:Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia. Blood 95(1):62, 2000
 
56) Tobal K et al:Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 95(3):815, 2000
 
57) Wattjes MP et al:Comparison of nested competitive RT-PCR and real-time RT-PCR for detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia. Leukemia 14:329, 2000
 
58) Campanini F et al:Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia. Haematologica 86(2):167, 2001
PubMed
59) Higuchi R et al:Kinetic PCR;Real time monitering of DNA amplification reaction. Biotechnology 11:1026, 1993
 
60) Heid CA et al:Real time quantitative PCR. Genome Res 6:986, 1996
PubMed
61) Kreuzer KA et al:Light Cycler technology for the quantitation of bcr/abl fusion transcripts. Cancer Res 59:3171, 1999
 
62) Kawai S et al:Quantification of hepatitis C Virus by TaqMan PCR;comparison with HCV amplicor moniter assay. J Med Virol 58:121, 1999
 
63) van Dongen JJ et al:Prognostic value of minimal residual disease in acute lymphoblastic leukaermia in childhood. Lancet 352:1731, 1998
PubMed
64) Ross AA:Minimual residual disease in solid tumor malignancies;a review. J Hematother 7:9, 1998
 
65) Leung W et al:Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 22:971, 1998
 
66) Naito H et al:Detection of tyrosine Hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polymerase chain reaction. Eur J Cancer 27:762, 1991
PubMed
67) Mattano LA Jr et al:Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 52:4701, 1992
PubMed
68) Burchill SA et al:Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 36:213, 2001
PubMed
69) Horibe K et al:Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol 36:203, 2001
PubMed
70) Cheung VG et al:Making and reading microarrays. Nat Genet 21:15, 1999
PubMed
71) Duggan DJ et al:Expression profiling using cDNA microarrays. Nat Genet 21:10, 1999
PubMed
72) Lipshutz RJ et al:High density synthetic oligonucleotide arrays. Nat Genet 21:20, 1999
PubMed
73) Chee M et al:Accessing genetic inforrnation with high-density DNA arrays. Science 274:610, 1996
 

4. 染色体検査法

P.78 掲載の参考文献
1) 桜井雅温:白血病の染色体に関する国際ワークショップ. 腫瘍染色体アトラス (阿部達生ほか編), 南江堂, 東京, 1986, p147
 
2) Hook EB:Exclusion of chromosomal mosaicism:table of 90%, 95% and 99% confidence limits and comments on use. Am J Hum Genet 29:94, 1977
 
3) Bauman JG et al:A new method for fluorescence microscopical localization of DNA sequences by in situ hybridizatuion of fluorochromelabelled RNA. Exp Cell Res 128:485, 1980
PubMed
4) Pinkel D et al:Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 83:2934, 1986
PubMed
5) Arif M et al:Detection of residual host cells in sex-mismatched bone marrow transplantation in various hematological disease by fluorescence in situ hybridization. Jpn J Cancer Res 88:420, 1997
 
6) Haferlach T et al:Which compartments are involved in Philadelphia chromosome positive chronic myeloid leukaemia? An answer at the single cell level by combining May-Grunwald-Giemsa staining and fluorescence in situ hybridization techniques. Br J Haematol 97:99, 1997
PubMed
7) Mark HFL et al:Sequential flow cytometry and fluorescence in situ hybridization for the study of formalin-fixed, paraffin-embedded breast cancer cells. Cancer Genet Cytogenet 100:129, 1998
 
8) Schrock E et al:Multicolor spectral karyotyping of human chromosomes. Science 273:494, 1996
PubMed
9) Kakazu N et al:Combined spectral karyotyping and DAPI banding analysis of chromosome abnormalities in myelodysplastic syndrome. Genes Chromosomes & Cancer 26:336, 1999
PubMed
10) Hilgenfeld E et al:Spectral karyotyping and fluorescence in situ hybridization detect novel chromosomal aberrations, a recurring involvement of chromosome 21 and amplification of the MYC oncogene in acute myeloid leukaemia M2. Br J Haematol 113:305, 2001
PubMed

5. 細胞免疫学的診断法

P.96 掲載の参考文献
1) 河本圭司ほか編:フローサイトメトリー入門, 医学書院, 東京, 1989
 
2) Sun T:Color atlas-Text of flow cytometric analysis of hematologic neoplasms, New York, IGAKU-SHOIN, 1993
 
3) Rothe G, Schmitz G for the Working Group on Flow Cytometry and Image Analysis:Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 10:877, 1996
 
4) Jennings CD et al:Recent advances in flow cytometry:Application to the diagnosis of hematologic malignancy. Blood 90:2863, 1997
 
5) Inaba T et al:CD45-negative acute leukemia in adulthood. Eur J Haematol 64:66, 2000
PubMed
6) Inaba T et al:T-cell associated antigen-positive B-cell lymphoma. Leuk Lymphoma 42:1161, 2001
 
7) 新堂隆人ほか:CD45白血病細胞同定におけるその有用性について(第一報). 第33回日本臨床病理学会近畿支部総会抄録集, 1990, p87
 
8) Johannson A et al:Phenotypic transition of CD4+ Tcells from CD45RA to CD45RO is accompanied by cell activation and proliferation. Cytometry 19:343, 1995
 
9) Yakura H:The role of protein tyrosine phosphatase in lymphocyte activation and differentiation. Critical ReViews in Immunology 14:311, 1994
PubMed
10) Sun T et al:Gating strategy for immunophenotyping of leukemia and lymphoma. Am J Clin Pathol 108:152, 1997
PubMed

6. タンパク分析法

P.110 掲載の参考文献
1) Shapiro AL et al:Molecular weight estimation of polypeptide chains by electrophoresis in SDS-polyacrylamide gels. Biochem Biophys Res Commun 28:815, 1967
PubMed
2) Towbin H et al:Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets:procedure and some applications. Proc Natl Acad Sci USA 76:4350, 1979
PubMed

7. 検査用検体の処理と保存

P.118 掲載の参考文献
1) Chomczynski P et al:Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156, 1987
PubMed
2) Schutte B et al:Flow cytometric deterrnination of DNA ploidy level in nuclei isolated from paraffin-embedded tissue. Cytometry 6:26, 1985
PubMed
3) Diaz-Cano SJ et al:DNA extraction from formalin-fixed, Paraffin-embedded tissues:protein digestion as a limiting step for retrieval of high-quality DNA. Diagn Mol Pathol 6(6):342, 1997
PubMed
4) Lasota J et al:Detection of the SYT-SSX fusion transcripts in formaldehyde-fixed, paraffin-embedded tissue:a reverse transcription polymerase chain reaction amplification assay useful in the diagnosis of synovial sarcoma. Mod Pathol 11(7):626, 1998
 
5) Desmaze C et al:Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. Cancer Genet Cytogenet 74:13, 1994
 
6) Dal Cin P et al:Cytogenetic and Fluorescence ln Situ Hybridization Investigation of Ring Chromosomes Characterizing a Specific Pathologic Subgroup of Adipose Tissu Tumors. Cancer Genet Cytogenet 68:85, 1993
 
7) 渡辺慶一ほか編:酵素抗体法, 改訂4版, 学際企画, 2002
 
8) 野口雅之:分子生物学的手法に用いる検体の保存. 病理と臨床 14(臨時増刊号):234, 1996
 
9) 日本病理学会編:病理組織標本作製技術. 病理技術マニュアル3, 医歯薬出版, 東京, 1981
 
10) 中山広樹ほか:バイオ実験イラストレイテッド, 第1巻, 秀潤社, 東京, 1995
 
11) 渋谷 誠ほか:細胞診標本を用いたfluorescence in situ hybridization (FISH) によるinterphase cytogeneticsの実際. 病理と臨床 12(4):475, 1994
 
12) 日本病理学会編:細胞診とその技術. 病理技術マニュアル6, 医歯薬出版, 東京, 1981
 
13) 日本組織培養学会編:組織培養の技術, 第3版, 基礎編, 朝倉書店, 東京, 1996
 
14) 武部 啓編:ヒト培養細胞および染色体診断マニュアル, 講談社サイエンティフィク, 東京, 1990
 

8. 腫瘍の遺伝子・免疫学的診断と臨床的意義

P.140 掲載の参考文献
1) Bennett JM et al:Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33(4):451, 1976
PubMed
2) Bennett JM et al:Proposal for the recognition of minirnally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 78(3):325, 1991
 
3) Bennett JM et al:Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intem Med 103(3):460, 1985
 
4) Rowley JD:Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 16(2):109, 1973
 
5) Miyoshi H et al:The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript EMBO J 12(7):2715, 1993
 
6) Okuda T et al:AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84(2):321, 1996
PubMed
7) Grimwade D et al:The importance of diagnostic cytogenetics on outcome in AML:analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92(7):2322, 1998
 
8) Bennett JM et al:A variant forrn of hypergranular promyelocytic leukaemia. Br J Haemato 144(1):169, 1980
 
9) Kakizuka A et al:Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha With a novel putative transcription factor, PML. Cell 66(4):663, 1991
PubMed
10) Huang ME et al:Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72(2):567, 1988
PubMed
11) Dyck JA et al:A novel macromolecular structure is a target of the promyelocyteretinoic add receptor oncoprotein. Cell 76(2):333, 1994
 
12) Alsabeh R et al:Acute myeloid leukemia with t(6;9)(p23;q34):association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol 107(4):430, 1997
 
13) Arthur DC et al:Panial deletion of the long arm of chromosome 16 and bone marrow eosinophuia in acute noriymphocytic leukemia:a new association. Blood 61(5):994, 1983
 
14) Liu P et al:Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science 261(5124):1041, 1993
 
15) Rubnitz JE et al:11q23 rearrangements in acute leukemia. Leukemia 10(1):74, 1996
PubMed
16) Soekaman D et al:The translocation (6;9)(p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features. Blood 79(11):2990, 1992
 
17) Lee-EJ et al:Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis. Leukemia 4(5):350, 1990
PubMed
18) Suzukawa K et al:Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 84(8):2681, 1994
PubMed
19) Bos JL:ras oncogenes in human cancer:a review. Cancer Res 49(17):4682, 1989
 
20) Tobal K et al:Mutation of the human FMS gene (M-CSF receptor )in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 4(7):486, 1990
PubMed
21) Wattel E et al:p53 mutabions are associated with resistance to chemotherapy and short survival in hematologic malignandes. Blood 84(9):3148, 1994
PubMed
22) Nakao M et al:Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1811, 1996
 
23) Yokota S et al:Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11(10):1605, 1997
 
24) 奈良信雄:ALLの診断プロトコル. Medical Technology 27(1):6, 1999
Medical*Online
25) Morphologic, immunologic, and cytogenetic (MIC) working classification of acute lymphoblastic leukernias. Report of the workshop held in Leuven, Belgium, April 22-23, 1985. First MIC Cooperabive Study Group. Cancer Genet Cytogenet 23(3):189, 1986
 
26) Harris NL et al:A revised European-American classification of lymphoid neoplasms:a proposal from the International Lymphoma Study Group. Blood 84(5):1361, 1994
 
27) Harris NL et al:World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues:report of the Clinical Advisory Committee meeting-Airlie House, virginia, November 1997. J Clin Oncol 17(12):3835, 1999
PubMed
28) 大島年照:急性白血病の診断. MP 15(3):435, 1998
 
29) 柵木信男ほか:2:染色体診断による臨床応用, B:急性リンパ性白血病. 臨床染色体診断法(古庄敏行ほか編), 金原出版, 東京, 1996, p600
 
30) Adolfo A et al:Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leikemia. Seminar Hematol 37(4):381, 2000
 
31) 清井 仁:免疫グロブリン遺伝子による微量残存白血病細胞の診断. 別冊医学のあゆみ(血液疾患 Ver.2-State of arts):297, 1998
 
32) van Dongen JJ et al:Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731, 1998
PubMed
33) Filipits M et al:Clinical relevance of drug resistant genes in malignant disease. Leukemia 10(Suppl 3):s10, 1996
 
34) Tonnelle C et al:Ikaros gene expression and leukemia. Leuk Lymphoma 43(1):29, 2002
PubMed
35) 喜多嶋康一:慢性骨髄性白血病. 最新内科学大系 19 白血病 (山村雄一ほか監修), 中山書店, 東京, 1992, p145
 
36) Chronic myeloid leukemia. in Cancer Cytogenetics (Heim S et al eds), 2nd ed, Wiley-Liss, New York, 1995, p33
 
37) Pasternak G et al:Chronic myelogenous leukemia:molecular and cellular aspects. J Cancer Res Clin Oncol 124:643, 1998
PubMed
38) Melo JV:The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 88:2375, 1996
PubMed
39) Pear WS et al:Efficient and rapid induction of a chronic myelogenous leukemialike myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92:3780, 1998
 
40) Lion T:Monitoring of residual disease in chronic myelogenous leukemia:methodological approaches and clinical aspects. Leukemia 10:896, 1996
PubMed
41) Bernstein R et al:Do chromosome abnormalities determine the type of acute leukemia that develops in CML? Leukemia 4:65, 1990
PubMed
42) Nakai H et al:Frequent p53 mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res 52:6588, 1992
PubMed
43) Takahashi N et al:Lineage involvement of stem cells bearing the Philadelphia chromosome in chronic myeloid leukemia in the chronic phase as shown by a combination of fluorescence-activated cell sorting and fluorescence in situ hybridization. Blood 92:4758, 1998
 
44) Carella AM et al:Autografting with Philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 93:1534, 1999
PubMed
45) Cross NCP et al:Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929, 1993
 
46) Radich JP et al:Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogenic marrow transplantation for chronic myeloid leukemia:Results and implications in 346 patients. Blood 85:2632, 1995
 
47) Guilhot F et al:Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337:223, 1997
PubMed
48) Kantarjian HM et al:Chronic myelogenous leukemia-Progress at the M.D. Anderson Cancer Center over the past two decades and future directions:First Emil J Freireich Award Lecture. Clin Cancer Res 3:2723, 1997
 
49) Mauro MJ et al:STI571:A paradigm of new agents for cancer therapeutics. J Clin Oncol 20:325, 2002
PubMed
50) Takatsuki K et al:ATL and HTLV-I -related diseases. Adult T-cell leukemia (K Takatsuki ed), Oxford press, London, 1994, p 1
 
51) Hattori T et al:Surface phenotype of Japanese adult T-cell leukemia cells characterized by monoclonal antibodies. Blood 58:645, 1981
PubMed
52) Matsuoka M et al:T3 surface molecules on adult T cell leukemia cells are modulated in vivo. Blood 67:1070, 1986
PubMed
53) Shirono K et al:Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia. Blood 73:1664, 1989
PubMed
54) Suzushima H et al:Double-negative (CD4- CD8-) T cells from adult T-cell leukemia patients also have poor expression of the T-cell receptor alpha beta/CD3 complex. Blood 81:1032, 1993
 
55) Yoshida M et al:Regulation of HTLV-I gene expression and its roles in ATL development. Adult T-cell leukemia (K Takatsuki ed), Oxford press, London, 1994, p28
 
56) Tamiya S et al:Two types of defective human T-lymphotropic virus type I (HTLV-I)provirus in adult T cell leukemia. Blood 88:3065, 1996
 
57) Sakashita A et al:Mutations of the p53 gene in adult T-cell leukemia. Blood 79:477, 1992
PubMed
58) Hatta Y et al:Homozygous deletions of the p15 (MST2) and p16 (CDKN2/MST1) genes in adult T-cell leukemia. Blood 85:2699, 1995
 
59) Tamiya S et al:Mutation of CD95 (Fas/Apo-1) genes in adult T-cell leukemia cells. Blood 91:3935, 1998
PubMed
60) 松岡雅雄:成人T細胞白血病リンパ腫. 悪性リンパ腫治療マニュアル(平野正美ほか編), 南江堂, 東京, 1998, p90
 
61) Shimoyama M:Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79:428, 1991
 
62) 安永純一朗ほか:抗HTLV-I 抗体陽性患者の管理の実際. 治療 84:307, 2002
Medical*Online
63) Harris NL et al:The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, Novemver 1997. Mod Pathol 13:193, 2000
 
64) 谷脇雅史:悪性リンパ腫のゲノム異常. 日本内科学会雑誌 90:27, 1999
 
65) 田丸淳一ほか:表面抗原を用いた悪性リンパ腫の診断-REAL分類に沿って-. 医学のあゆみ 188:901, 1999
 
66) The Non-Hodgkin's lymphoma classification project. Blood 89:3909, 1997
PubMed
67) 加納 正:骨髄腫と特発性単クローン性免疫グロブリン血症の境界領域をどのように考えるか. 日本臨床免疫学会会誌 6:352, 1983
 
68) 加納 正:多発性骨髄腫の臨床. 日本内科学会雑誌 87:1897, 1998
 
69) 河野道生:多発性骨髄腫. 現代医療 31:1861, 1999
 
70) Fujii R et al:MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol 105:131, 1999
 
71) San Miguel JF et al:Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma:a tool for comparing the efficacy of different treatment strategies and predicting outcome. Blood 99:1853, 2002
PubMed
72) Avet-Loiseau H et al:Oncogenesis of multiple myeloma:14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 99:2185, 2002
 
73) Desikan R et al:Results of high-dose therapy for 1000 patients with multiple myeloma:durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95:4008, 2000
PubMed
74) Tricot G et al:Predicting longterm (≧5years) event-free survival in multiple myeloma patients following planned tandem autotransplants. Br J Haematol 116:211, 2002
 
75) Facon T et al:Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 97:1566, 2001
 
76) Fonseca R et al:Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (Δ13) in multiple myeloma:an Eastern Cooperative Oncology Group Study. Cancer Res 62:715, 2002
 
77) Schneider U et al:Two subsets of peripheral blood plasma cells defined by differential expression of CD45 antigen. Br J Haematol 97:56, 1997
PubMed
78) Rawstron AC et al:Circulating plasma cells in multiple myeloma:characterization and correlation with disease stage. Br J Haematol 97:46, 1997
PubMed
79) Hallek M et al:Multiple myeloma:Increasing evidence for a multistep transformation process. Blood 91:3, 1998
PubMed
80) Mahmoud MS et al:Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity. Blood 94:3551, 1999
PubMed
81) Taniwaki M et al:Nonrandom chromosomal rearrangements of 14q32. 3 and 19p13. 3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84:2283, 1994
PubMed
82) Nishida K et al:The Ig heavy chain gene is frequently involved in chromosomal translocations in multiple myeloma and plasma cell leukemia as detected by in situ hybridization. Blood 90:526, 1997
PubMed
83) Chesi M et al:The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts. Blood 92:3025, 1998
 
84) Iida et al:Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17:226, 1997
PubMed
85) Bennett JM et al:Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51(2):189, 1982
PubMed
86) Kataoka A et al:RT-PCR detection of breast cancer cells in sentinel lymph nodes. Int J Oncol 16:1147, 2000
PubMed
87) Mori M et al:Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas. J Clin Oncol 16:128, 1998
PubMed
88) Yamashita K et al:Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 6:1169, 2000
PubMed

9. 遺伝子・免疫学的検査の治療への応用

P.202 掲載の参考文献
1) Ryan DH et al:Detection of residual disease in acute leukemia using immunological markers. Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias (Bennett JM et al ed), Kluwer Academic, Norwell, MA, 1988, p 173
 
2) Lee MS et al:Deteceion of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science 237:175, 1987
 
3) Kawasaki ES et al:Diagnosis of chronic myeloid and acute lymphoblastic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acid Sd USA 85:5698, 1988
 
4) van Dongen JJ et al:Analysis of immunoglobuhn and T cell receptor genes. Part I:Basic and techrical aspects. Clin Chim Acta 198:1, 1991
 
5) Yokota S et al:Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77:331, 1991
PubMed
6) d'Auriol L et al:In vitro amplification of T cell gamma gene rearrangements:a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemias. Leukemia 3:155, 1989
 
7) Yamada M et al:Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-detemining region (CDR-III)- specific probes. Proc Natl Acad Sci USA 86:5123, 1989
 
8) Inoue K et al:WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84:3071, 1994
 
9) van Dongen JJ et al:Prognostic value of minimal residual disease in acute lyrmphoblastic leukaemia in childhood. Lancet 352:1731, 1998
PubMed
10) Okamoto T et al:Minimal residual disease in early phase of chemotherapy reflect poor outcome in children with acute lymphoblastic leukemia-Aretrospective study by the Children's Cancer and Leukemia Study Group in Japan-. Leukemia and Lymphoma 43(5):1001, 2002
 
11) Coustan-Smith E et al:Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96(8):2691, 2000
PubMed
12) Panzer-Grurnayer ER et al:Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 95:790, 2000
 
13) Brisco MJ et al:Early resistance to therapy during induction in childhood acute lymphoblastic leukemia. Cancer Res 60:5092, 2000
PubMed
14) Mortuza FY et al:Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 20:1094, 2002
PubMed
15) Tobal K et al:Molecular quantitation of minimal residual disease in acute myeloid leukemia with t(8;21) can identify patients in durable remission and predict clinical relapse. Blood 95(3):815, 2000
 
16) Diverio D et al:Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocydc leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Blood 92(3):784, 1998
PubMed
17) Mori T et al:A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity. Leukemia 9:1233, 1995
 
18) Behm FG et al:Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 87:1134, 1996
 
19) Campana D et al:Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 38:139, 1999
PubMed
20) Coustan-Smith E et al:N-CAM(CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. Leukemia 7:853, 1993
PubMed
21) Lanza F et al:Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br J Haematol 103:110, 1998
PubMed
22) Chen JS et al:Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood 97:2115, 2001
PubMed
23) Dworzak MN et al:Progriostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 99:1952, 2002
PubMed
24) Venditti A et al:Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 96:3948, 2000
PubMed
25) McKenna RW et al:Immunophenotypic analysis of hematogones (B-lymphocyteprecursors) in 662 corrsecutive bone marrow specimens by 4-color flow cytometry. Blood 98:2498, 2001
PubMed
26) Burchill SA et al:Minirnal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Onco136:213, 2001
PubMed
27) Horibe K et al:Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Onco136:203, 2001
PubMed
28) Wang Y et al:Expression of Protein Gene Product 9. 5 and Tyrosine Hydroxylase in Childhood Small Round Cell Tumors. Clin Cancer Res 6:551, 2000
PubMed
29) Cheung IY et al:Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. Med Pediatr Oncol 35:632, 2000
PubMed
30) Chemg IY et al:Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 7:1698, 2001
 
31) 白井千晶:神経芽腫における逆転写PCR法による微小残存腫瘍の検出. 日児誌 101:80, 1997
 
32) Yamane S et al:Disseninated retinoblastoma successfully treated myeloabrative chemotherapy implication for molecular detection of minimal residual disease. Bone Marrow Transplant 23:971, 1999
 
33) Barr FG:The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomyosarcoma. Cancer Res 59:1711s, 1999
PubMed
34) 細井 創ほか:横紋筋肉腫の新しい診断マーカー-MyoD1とmyogenin-. 小児科臨床 50:709, 1997
Medical*Online
35) Gattenloehner S et al:A comparison of MyoD1 and Fetal Acetylcholine Receptor Expression in Childhood Tumors and Normal Tissues. J Mol Diag 1:23, 1999
 
36) 角能庸介ほか:腫瘍特異的キメラmRNAによる軟部肉腫の分子病理学的診断. 小児科臨床 50:729, 1997
Medical*Online
37) PBSCT研究会小児分科会内部資料
 
38) 東 寛ほか:自家造血幹細胞移植術後3ヵ月で肺を中心とした全身転移が確認された神経芽腫の1例. 小児がん 33:473, 1996
 
39) Gribben JG et al:Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymPhoma. N Engl J Med 325(22):1525, 1991
PubMed
40) Gribben JG et al:Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83(12):3800, 1994
PubMed
41) Sharp JG:Detection and clinical significance of minimal tumor cell contamination of peripheral stem cell harvests. Int J Cell Clonong 10:92, 1992
 
42) Hardingham JE et al:Molecular detection of residual lymphoma cells in peripheral blood stem cell harvests and following autologous transplantation. Bone Marrow Transplant 11(1):15, 1993
PubMed
43) Hardingham JE et al:Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 13(5):1073, 1995
PubMed
44) Corradini P et al:Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografling. Blood 89(2):724, 1997
 
45) Bartram CR et al:Detection of minimal residual disease by polymerase chain reactions. Haematology and Blood Transfusion. Vol 34, Springer Verlag, Berlin, 1992, p171
 
46) Kolb HJ et al:Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86(5):2041, 1995
 
47) Collins RH Jr et al:Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15(2):433, 1997
PubMed
48) Weinstein MP et al:The clinical significance of positive blood cultures in the 1990s:a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin lnfect Dis 24:584, 1997
PubMed
49) 造血幹細胞移植マニュアル(小寺良尚ほか監修), 日本医学館, 1995
 
50) 大林民典:深在性真菌症の血清診断. 臨床検査 43:157, 1999
 
51) Obayashi T et al:Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episods. Lancet 345:17, 1995
 
52) 山本善裕ほか:真菌症の抗原検査. Lab Clin Pract 14:112, 1996
 
53) Yasuoka A et al:(1→3)-β-D-glucan as a quantitative serological marker for Pneumocystis carinii pneumonia. Clin Diagn Lab Immunol 3:197, 1996
 
54) Gondo H et al:Cytomegalovirus(CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 86:130, 1994
PubMed
55) サイトメガロウイルス感染症. 造血幹細胞移植ガイドライン, 日本造血細胞移植学会編, 1999年7月
 
56) MM Aspin et al:Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients. J Clin Microbiol 32:2266, 1994
PubMed
57) Boeckh M et al:Plasma polymerase chainreaction for cutomegalovirus DNA after allogenic bone marrow transplantation. Transplantation 64:108, 1997
 
58) Tanabe K et al:Comparative study of cytomegalovirus(CMV) antigenemia assay, polyrnerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation. Transplantation 64:1721, 1997
PubMed
59) Lo CY et al:Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients:a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemiaa by CMV pp65 assay. Clin Transplant 11:286, 1997
PubMed
60) Matsunaga T et al:Use of PCR serum in diagnosing and monitoring cytomegalovirus reactivation in bone marrow transplant recipients. Int J Haematol 69:105, 1999
 
61) Honda J et al:Rapid and sesitive diagnosis of cytomegalovirus and Pneumocystis carinii pneumonia in patients with haematological neoplasis by using capillary polymerase chain reaction. Br J Haematol 86:138, 1994
 
62) Eckart P et al:Detection of human cytomegalovirus in renal transplantation:comparison of four diagnostic methods:DNA in sera by polymerase chain reaction(PCR), DNA in leukocyte by PCR, pp65 leukocytic antigenemia, and viremia. Tansplant Proceed 29:2387, 1997
 
63) Boivin G et al:Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects. J Clin Microbiol 36:2509, 1998
PubMed
64) Aitken C et al:Use of molecular assays in diagnosis and monitoring of Cytomegalovirus disease following renal transplantation. J Clin Microbiol 37:2804, 1999
PubMed
65) Razonable RR et al:Role of the laboratory in diagnosis and management of Cytomegalovirys infection in hematopoietic stem cell and solid-oragan transplant recipients. J Chn Microbiol 40:746, 2002
 
66) Edman JC et al:Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature 334:519, 1988
PubMed
67) Stringer JR:Pneumocystis carinii:what is it, exaclly? Clin Microbiol Rev 9:489, 1996
PubMed
68) Ribes JA et al:PCR detection of Pneumocystis carinii bronchoalveolar lavage specimens:Analysis of sesitivity and specificity. J Clin Microbiol 35:830, 1997
 
69) Helweg-Larsen J et al:Diagnostic use of PCR for detection of Pneumocystis carinii in oral wash samples. J Clin Microbiol 36:2068, 1998
 
70) Wakefield AE et al:Detection of Pneumocystis carinii with DNA amplification. Lancet 336:451, 1990
PubMed
71) Weig M et al:Usefulness of PCR for diagnosis of Pneumocystis carinii pneumonia in different patient groups. J Clin Microbiol 35:1445, 1997
PubMed
72) Weig M et al:Correlation of Pneumocystis carinii PCR with clinical diagnosis in immunocompromised patients. Labcet 347:1266, 1996
 
73) Rabodonirina M et al:Rapid detction of Pneumocystis carinii in bronchoalveolar lavage specimens from human immunodeficiency virus-infected patients:use of a simple DNA extraction procedure and nested PCR. J Clin Microbiol 35:2748, 1997
 
74) Don RH et al:'Touchdown' PCR to circumvent spurious prining during gene amplification. Nucleic Acid Res 19(14):4008, 1991
 
75) Olsson M et al:Detection of Pneumocystis carinii DNA in sputum and bronchoalveolar lavage samples by polymerase chain reaction. J clin Microbiol 31:221, 1993
PubMed
76) Palladino S et al:Use of real-time PCR and LightCycler system for the rapid detection of Pneumocystis carinii in respiratory specimens. Diagn Microbiol Infect Dis 39(4):233, 2001
PubMed

書評

最近チェックした商品履歴

Loading...